Sagimet Biosciences Inc.
Sagimet Biosciences (Nasdaq: SGMT) is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors for diseases linked to excess palmitate production. Its lead candidate, denifanstat, is an oral, once-daily drug in development for metabolic dysfunction-associated… From the company’s description.
In fiscal 2025, Sagimet Biosciences Inc. reported a net loss of $51.04M. Operations used $45.65M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Sagimet Biosciences Inc. does
In the company’s own words
Sagimet Biosciences (Nasdaq: SGMT) is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors for diseases linked to excess palmitate production. Its lead candidate, denifanstat, is an oral, once-daily drug in development for metabolic dysfunction-associated steatohepatitis (MASH), acne and selected cancers; the company is also developing TVB-3567 for acne and a denifanstat combination with resmetirom for cirrhotic MASH. Sagimet’s development programs span MASH, acne and oncology, with denifanstat development and commercialization rights in Greater China licensed to Ascletis, which is conducting acne trials there. In 2025, the company completed a Phase 1 pharmacokinetic study of denifanstat with resmetirom, while TVB-3567 entered a Phase 1 trial. Sagimet’s principal activities are research and clinical development, rather than marketing approved products. Its website is https://www.sagimet.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FOSTER CITY, CA
- Fiscal year end
- December
- CIK
- 1400118
- SIC
- 2834
Financial performance, year by year
Fiscal 2023–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Sagimet Biosciences Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Sagimet Biosciences Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Sagimet Biosciences Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Sagimet Biosciences Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Sagimet Biosciences Inc.'s last four quarterly filings that the numbers alone won't show?”